Symbolbild · KI-generiert
Precision BioSciences
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Precision BioSciences is a biotechnology company developing therapies and products based on its ARCUS genome editing platform. The company pursues applications in in vivo gene therapy as well as CAR-T cell therapies for cancer. It also licences the technology platform to other companies.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Precision BioSciences | DTIL | NASDAQ | 180 Mio. USD |
| Vector Science and Therapeutics Corp. | PAIN | TSXV | 179 Mio. USD |
| High Tide Inc. | HITI | TSXV | 186 Mio. USD |
| Auxly Cannabis Group Inc. | XLY | TSX | 189 Mio. USD |
| Aurora Cannabis Inc. | ACB | TSX | 170 Mio. USD |
| RCI Hospitality Holdings | RICK | NASDAQ | 192 Mio. USD |
| CareRx Corporation | CRRX | TSX | 164 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.